Study To Check The Analgesic And Anti-Inflammatory Effects Of Atorvastatin In Patients Undergoing Abdominal Surgery
NCT ID: NCT00902967
Last Updated: 2009-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
40 participants
INTERVENTIONAL
2009-07-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
NCT00756886
Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose
NCT01543555
Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI
NCT02590653
Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging
NCT00920101
Atorvastatin in Perioperative Vascular Surgery - Pilot Study
NCT00610545
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Method of Randomization: Computer Generated Table
No. of patients to be recruited: 40
Accept Healthy Volunteers: No
Drugs to be administered: Atorvastatin to 20 patients and placebo to 20 patients
Mode of drug administration: Oral
Duration of Study: 3 weeks
Patients who attend the Surgical O.P.D and the Obstetrics and Gynaecology O.P.D and are diagnosed with any condition that requires elective abdominal surgery under spinal anaesthesia will be chosen for screening. Patients undergoing day care surgery with spinal anaesthesia and an abdominal incision will also be included for screening.
Two weeks before the decided date of surgery the patients will be called for screening. The patients will first be screened for obesity, risk factors for CVS diseases and blood will be withdrawn for estimation of serum lipid levels. Further risk assessment of these patients will be done according to the NCEP ATP III Guidelines (2004 Revision of NCEP Adult Treatment Panel III Guidelines). If the patient is under the moderate risk category and fits in the inclusion criteria he/she will be called the next week for starting atorvastatin/placebo.
Patients who are defined as dyslipidemic in the moderate risk category according to NCEP ATP III Guidelines i.e patients who would benefit from statin therapy will be given atorvastatin 10 mg or placebo started one week before their expected date of surgery. They will be explained the possible A.D.R of statin therapy. Informed consent form will be filled.
On the day of the surgery the patient will be explained the Visual Analouge Scale and the Wong Pain Scale. After the operation the patients will be started on S.O.S analgesic therapy. The protocol used will be the same as followed in the surgical wards. In case of severe pain opioids will be used. For other types of pain which can be tolerated by the patients Diclofenac Sodium will be used.
The patient will be monitored after the surgery for the total dose of analgesics required for the relief of pain. Further the time of first dose of analgesic required after operation will be noted. The patient will be monitored for pain at the incision site 2, 4, 6, 12, 24 hours after the operation using the visual analogue scale and the Wong Pain Scale. Later using the abovementioned scales the patient's pain will be monitored twice daily until the patient is discharged. The McGill Pain Questionnaire will be given to the patient on the first day and every day thereafter till the patient is discharged. After discharge the patient will followed up on the day of their suture removal and pain scores will be evaluated. The patient will be asked to come weekly till the end of the study period.
Blood will be withdrawn for the estimation of serum lipid levels, total leukocyte counts, C - reactive protein and TNF-α levels at baseline(i.e day of starting therapy), on the day of the surgery before the surgery and at the fourth postoperative day. All blood samples will be taken between 10A.M-12P.M Wound healing will be monitored on a daily basis until discharge and weekly thereafter. The attending surgeon will monitor the wound for discharge, swelling, etc. Additional signs of inflammation and infection like swelling, fever, erythema will also be monitored for.
The patients will be instructed to take atorvastatin or placebo once a day for three weeks (One week preoperative and two weeks postoperative). At the end of this period the patient will be asked to continue statins from outside. In the event that the patient is unable to afford the medication he will be weaned off the statin in a gradual manner.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
Atorvastatin
Atorvastatin 10 mg, once a day dosing at night after meals
2
Placebo tablets of similar shape and color given at night time dosing
Placebo
Placebo tablets of similar shape size and color given once a day at night time after meals
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Atorvastatin 10 mg, once a day dosing at night after meals
Placebo
Placebo tablets of similar shape size and color given once a day at night time after meals
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who will be undergoing abdominal surgery under spinal anaesthesia
3. Patients who will undergo non-bowel abdominal surgery with an abdominal incision
4. Understands and agrees to comply with all study procedures including the daily treatments and follow-up visits
5. Able to understand and is voluntarily willing to sign an informed consent form for this study
6. Weight between 50 and 120 kg
Exclusion Criteria
2. Any emergency operations
3. Surgery in patients in whom the chances of infection are very high. Example peritonitis, cystitis, appendical abscess, perforations, etc
4. Laparoscopic Surgery
5. Pregnant or nursing, or with the ability to become pregnant and not using an accepted form of birth control
6. Any active Cancer
7. Uncontrolled diabetes mellitis
8. Untreated hypertension
9. Psychotic disorder(s), dementia, mental retardation, or other organic mental disorders (subjects who are not mentally and physically able to personally consent for participation in this study are not eligible)
10. Any other (including acute) condition, which in the opinion of the investigator, is likely to cause non-compliance or significantly impact treatment outcomes
11. Sensitivity to the study drug or its components
25 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
B. J. Medical College, Pune
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
B. J. medical College & Sassoon General Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pharmacology, Sassoon General Hospitals
Pune, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASU 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.